Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Veranova Fentanyl

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Duragesic (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,676Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Health officials warn of veterinary sedative in illegal drug
    Health officials warn of veterinary sedative in illegal drug

    07 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-officials-warn-veterinary-sedative-illegal-drug-supply-2026-04-02/

    REUTERS
    07 Apr 2026
    Share Share
    AI Model Designs New Treatment Candidate For Opioid Addiction
    AI Model Designs New Treatment Candidate For Opioid Addiction

    06 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/research/ai-model-designs-new-treatment-opioid-addiction-cuts-cravings-rats

    FIERCE BIOTECH
    06 Apr 2026
    Share Share
    Counterx Therapeutics Licenses Novel Antibodies, Vaccines
    Counterx Therapeutics Licenses Novel Antibodies, Vaccines

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/counterx-therapeutics-executes-exclusive-licensing-agreement-for-portfolio-of-novel-monoclonal-antibody-and-vaccine-candidates-targeting-fentanyl-and-opioid-overdose-302709052.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Elysium Therapeutics Secures $7.5M To Advance Oral Fentanyl
    Elysium Therapeutics Secures $7.5M To Advance Oral Fentanyl

    28 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/elysium-therapeutics-raises-7-5-million-safe-round-to-accelerate-development-of-novel-rescue-therapy-designed-to-specifically-combat-oral-fentanyl-overdose-302671914.html

    PR NEWSWIRE
    28 Jan 2026
    Share Share
    CounterX Therapeutics Announce Publication Demonstrating CTRX-101
    CounterX Therapeutics Announce Publication Demonstrating CTRX-101

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/counterx-therapeutics-announces-publication-demonstrating-ctrx-101-an-anti-fentanyl-monoclonal-antibody-therapy-reverses-fentanyl-induced-overdose-in-preclinical-model-302597828.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    SUBLOCADE® Induction Shows Promise In Enhancing Opioid Use
    SUBLOCADE® Induction Shows Promise In Enhancing Opioid Use

    15 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-evidence-supports-rapid-sublocade-induction-as-a-strategy-to-improve-retention-in-opioid-use-disorder-treatment-302584003.html

    PR NEWSWIRE
    15 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.